OBJECTIVE To guide the clinical medication of gastric cancer， enhance patients’ survival rates， improve patients’ quality of life， and provide a reference for clinicians in making treatment decisions. METHODS The nominal group method was employed， wherein members of the expert group from the Department of Oncology at Chongqing University Cancer Hospital collaboratively discussed and established the outline for the preparation of the Expert Consensus on Drug Treatment of Gastric Cancer. The writing team of experts systematically searched， analyzed， and summarized the relevant content outlined， as well as formulated consensus statements based on the current situation in China， clinical needs， and research evidence. After multiple rounds of meetings and discussions， the experts from the Chemotherapy Group of the Chongqing Medical Oncology Branch and the Special Committee on Rare and Difficult Cancers of Chongqing Medical and Biotechnology Association revised the recommendation and ultimately reached the consensus content and recommendation level through voting. RESULTS & CONCLUSIONS This consensus encompasses perioperative drug therapy for gastric cancer， first-line drug therapy for advanced metastatic gastric cancer， second-line drug therapy for advanced metastatic gastric cancer， third-line and subsequent drug therapies for advanced gastric cancer， and drug therapy for peritoneal metastasis of gastric cancer. The release of this consensus offers standardized management suggestions for the individualized medication of gastric cancer by medical institutions in China， which is of great significance for enhancing the clinical efficacy and medication safety associated with gastric cancer treatment.